Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

A report released Thursday said highly processed foods, exposure to chemicals and excessive use of prescription drugs are ...

They're brightly colored, packed in enticing boxes and often marketed as healthy -- but many cereals today are actually less ...

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Analysts' ratings for Septerna SEPN over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but there could still be a solid upside left in the stock if short-term price ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...